CytomX Therapeutics, Inc. (CTMX) stock
Close on Nov 11, 2026Market cap $464.13MP/E –Yield –
CytomX Therapeutics, Inc. saw revenue fall 87.7% to $14.03M over the twelve months to Sep 30, 2026. Operating income fell 508.2% to -$94.89M, moving the operating margin from 20.5% to -676.5%. Free cash flow was -$51.00M. At the latest close the market valued the company at $464.13M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $464.13M
- P/E ratio
- –
- Price to sales
- 33.09
- Price to book
- 1.63
- Dividend yield
- –
- Free cash flow yield
- -10.99%
Fundamentals
- Revenue
- $14.03M
- Net income
- -$85.42M
- EPS, diluted
- -$0.46
- Free cash flow
- -$51.00M
- Book value per share
- $1.30
- Diluted shares
- 219M
Trading
- Next earnings
- Mar 15, 2027 (estimated, before the open)
- Previous close
- $1.98
- Open
- $1.99
- Day's range
- $1.96 – $2.17
- Volume
- 4,992,599
- Average volume (20 days)
- 5,273,666
- Index membership
- Russell 2000 (since Jun 2026), Russell 3000
- Beta (5 years)
- 1.60
- 52-week range
- $1.90 – $8.21
- RSI (14 days)
- 42.0
- Volatility (1 year)
- 85.5%
- Relative volume
- 1.32×
- WACC
- 12.9%
On 2 of our idea lists: More cash than they're worth, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CTMX | S&P 500 | Difference | CTMX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -17.1% | -2.4% | −14.7 pts | ||
| 3 months | -38.3% | -1.2% | −37.1 pts | ||
| Year to date | -50.0% | +12.3% | −62.3 pts | ||
| 1 year | -48.0% | +12.4% | −60.5 pts | ||
| 3 years | +82.1% | +78.8% | +3.2 pts | +22.1% | +21.4% |
| 5 years | -69.6% | +75.2% | −144.8 pts | -21.2% | +11.9% |
| 10 years | -81.0% | +311.1% | −392.1 pts | -15.3% | +15.2% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases CytomX Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About CytomX Therapeutics
Pharmaceutical Preparations
CytomX is a clinical-stage biopharmaceutical company that develops conditionally activated biologic therapies for cancer treatment. Its PROBODY platform designs biologics that stay inactive in healthy tissue and activate in tumor microenvironments through protease cleavage. The pipeline includes antibody-drug conjugates, T-cell engagers, cytokines, and messenger RNA. Its lead investigational programs include varsetatug masetecan, an antibody-drug conjugate targeting EpCAM for colorectal cancer, and CX-801, a masked interferon alpha-2b cytokine for advanced melanoma. The company collaborates with pharmaceutical partners, including Amgen, Bristol Myers Squibb, Astellas, Regeneron, and Moderna, and targets oncology patient populations.
Company profile, executives and historyCytomX Therapeutics stock: common questions
What is CytomX Therapeutics's stock price?
CTMX closed at $2.13 on Nov 11, 2026, up 7.58% on the day. Over the past 52 weeks it traded between $1.90 and $8.21.
What is CytomX Therapeutics's market cap?
CytomX Therapeutics was worth $464.13M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CTMX's P/E ratio?
CytomX Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.46), so it has no meaningful P/E ratio.
How much revenue does CytomX Therapeutics make?
CytomX Therapeutics reported revenue of $14.03M for the twelve months to Sep 30, 2026, down 87.7% from a year earlier.
Does CytomX Therapeutics pay a dividend?
No. CytomX Therapeutics has not paid a cash dividend over the last twelve months.
When does CytomX Therapeutics report earnings next?
CytomX Therapeutics is expected to report Q4 FY2026 results on Mar 15, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has CTMX stock performed over the past year?
Including dividends, CTMX returned -48.0% over the past year, against +12.4% for the S&P 500.
How many CTMX shares are sold short?
45M shares were sold short at the latest FINRA report, 21.08% of the float, or 12.0 days of average trading volume.
Who are CytomX Therapeutics's competitors?
Companies most similar to CytomX Therapeutics by business, industry and size include JANX, PYXS, CBIO, PRLD, ADAG.
See a number that looks wrong?